2. >>Business
  3. >>Deals

Aspen Explains Logic Behind €642m Mylan Thrombosis Deal

Transaction Forms Part Of Company Overhaul

 
• By Dean Rudge

Aspen Pharmacare last week announced the sale of its thrombosis business in Europe to Mylan for €642m ($762m). CEO Stephen Saad faced investors to detail the rationale for the US firm and what the planned transaction means for Aspen, including its material debt pile.

Agreement business handshake partnership deal as a solution strategy with a team coming together out of tangled twisted roads on to a bridge to find a common goal.
Aspen and Mylan have shaken hands on a deal providing for Aspen's thromobsis business in Europe • Source: Shutterstock

Significant synergies and economies of scale provided the logic for Mylan’s planned €642m ($762m) purchase of Aspen Pharmacare’s thrombosis business in Europe, according to the South African firm.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business